✨ Free AI Report
Horizon Therapeutics plc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Horizon Therapeutics plc
Company Research

Horizon Therapeutics plc: Business Overview, Financials & Competitive Analysis

Horizon Therapeutics was a global biopharmaceutical company focused on researching, developing, and commercializing medicines for rare diseases, autoimmune conditions, and severe inflammatory diseases. The company was...

Analyst-debate audio for Horizon Therapeutics plc

AskCyborg analysts argue the bull and bear cases for Horizon Therapeutics plc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Strong rare disease biopharmaceutical company with proven commercial execution, now a subsidiary of...

Read the full analyst-debate transcript →
Industry Orphan Drugs
5 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Horizon Therapeutics plc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Horizon Therapeutics plc Overview

Pro stress-test →

Horizon Therapeutics was a global biopharmaceutical company focused on researching, developing, and commercializing medicines for rare diseases, autoimmune conditions, and severe inflammatory diseases. The company was acquired by Amgen in December 2023 and is no longer independently traded. Prior to acquisition, Horizon operated through Orphan and Rheumatology and Inflammation segments with key commercial medicines including KRYSTEXXA, TEPEZZA, and UPLIZNA.

Strategic Profile

Pro stress-test →

Horizon positioned itself as a high-growth biotech company specializing in orphan and rare disease therapeutics, with strong commercial execution in immunomodulation. The company demonstrated consistent double-digit revenue growth and operated manufacturing facilities in Ireland, reflecting a regional presence in biopharma development.

Competitive Landscape

Pro stress-test →

Horizon competed in the rare disease and rheumatology therapeutics markets against other specialty pharma companies and biopharmaceutical firms. Primary competitors included other orphan drug developers and rheumatology specialists, though the company differentiated through focused immunomodulation strategy and strong commercial execution in niche markets.

Industry Context

Horizon Therapeutics plc operates in Orphan Drugs.

Key facts

Founded: 2008 · Headquarters: Dublin, Ireland · Employees: N/A · Revenue: $1.9B+ (pre-acquisition) · Market cap: N/A (Acquired December 2023)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Horizon Therapeutics plc.

  • TEPEZZA launched with exceptional rapid uptake in thyroid eye disease market, significantly exceeding initial expectations
  • KRYSTEXXA experienced 46% year-over-year sales growth driven by immunomodulation strategy success
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2023Acquired by Amgen, delisted from NASDAQ with final trade on December 8, 2023
  • Q2 2023Reported double-digit year-over-year growth and mid-teens sequential growth
  • +1 moreTrack every material event for Horizon Therapeutics plc as it happens. Explore monitoring →
Get alerted when Horizon Therapeutics plc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Regeneron PharmaceuticalsBiopharmaceutical company developing specialty medicines→Ultragenyx PharmaceuticalBiopharmaceutical company focused on rare and ultra-rare genetic diseases→Sesen BioRare disease biopharmaceutical company specializing in immunotherapy→Agios PharmaceuticalsBiopharmaceutical company developing therapies for rare metabolic disorders→Athena TherapeuticsRare disease focused biopharmaceutical company in neurological and genetic disorders→

Compare Horizon Therapeutics plc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Horizon Therapeutics plc operates in Orphan Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Orphan Drugs research →
NEW · MCP server

Ask your AI assistant about Horizon Therapeutics plc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Horizon Therapeutics plc and its top competitor on Cyborg Score”
“What did Horizon Therapeutics plc do this quarter?”
“Is Horizon Therapeutics plc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Horizon Therapeutics plc do?+
Horizon Therapeutics was a global biopharmaceutical company focused on researching, developing, and commercializing medicines for rare diseases, autoimmune conditions, and severe inflammatory diseases. The company was...
What is Horizon Therapeutics plc's Cyborg Score?+
Horizon Therapeutics plc has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Horizon Therapeutics plc's main competitors?+
Named competitors include Regeneron Pharmaceuticals, Ultragenyx Pharmaceutical, Sesen Bio, Agios Pharmaceuticals. The full competitive landscape is in the AskCyborg report.
How can I get the full Horizon Therapeutics plc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Horizon Therapeutics plc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Horizon Therapeutics plc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.